Read by QxMD icon Read

Therapeutic Advances in Drug Safety

Jules C Hancox, Rachel E Caves, Stéphanie C M Choisy, Andrew F James
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Drug Safety
Sangeeta Sharma, Fauzia Tabassum, Sarbjeet Khurana, Kaveri Kapoor
BACKGROUND: To explore interprofessionals' perceptions about patient safety, particularly medication safety and associated factors and barriers. METHODS: A total of 389 respondents were recruited using convenience sample in the cross sectional survey. RESULTS: Medication safety was perceived as somewhat safe (60%). One-third of respondents witnessed 3-4 or more medication errors (MEs) within the past 1 year. Out of that, one quarter were reportedly, sentinel events...
December 2016: Therapeutic Advances in Drug Safety
L Aït Moussa, O El Bouazzi, S Serragui, D Soussi Tanani, A Soulaymani, R Soulaymani
OBJECTIVE: High concentrations of antituberculosis (anti-TB) drugs can be associated with many adverse drug reactions (ADRs). The objective of this study was to examine the plasma concentrations of rifampicin (RMP) and isoniazid (INH) in patients with and without ADRs. METHODS: Concentration monitoring data of patients treated with anti-TB drugs were retrospectively analyzed from 2009 to 2011. RMP and INH plasma concentrations were measured 2 and 3 h after drug administration respectively using high-performance liquid chromatography...
December 2016: Therapeutic Advances in Drug Safety
Nidhi Jain, Malvi Savani, Manyoo Agarwal, Christopher W Sands
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Drug Safety
Dominique Elie, Saeid Noohi, André Do, Artin Mahdanian, Ching Yu, Marilyn Segal, Karl J Looper, Soham Rej
No abstract text is available yet for this article.
October 2016: Therapeutic Advances in Drug Safety
Shelly L Gray, Joseph T Hanlon
Use of medications with anticholinergic activity is widespread in older adults. Several studies have highlighted that anticholinergic use may be associated with an increased risk of dementia. The objective of this narrative review is to describe and evaluate studies of anticholinergic medication use and dementia and provide practical suggestions for avoiding use of these medications in older adults. A comprehensive review of the literature, citations from recent reviews and the author's personal files was conducted...
October 2016: Therapeutic Advances in Drug Safety
Katherine Warren, Helena Burden, Paul Abrams
Overactive bladder is a common condition, which significantly affects people's quality of life. The use of anticholinergic medication has been the mainstay of managing overactive bladder when conservative measures are not enough. Many patients stop anticholinergic medication because of the side effects and more recently the concerns about the effect of an anticholinergic burden and the development of dementia have been studied. Activation of β3 adrenoceptors has been shown to relax the detrusor muscle and subsequently lead to the development of the first β3 adrenoceptor agonist...
October 2016: Therapeutic Advances in Drug Safety
Christopher R Newey, Dolora Wisco, Premkumar Nattanmai, Aarti Sarwal
BACKGROUND: Refractory status epilepticus is often treated with third-line therapy, such as pentobarbital coma. However, its use is limited by side effects. Recognizing and preventing major and minor adverse effects of prolonged pentobarbital coma may increase good outcomes. This study retrospectively reviewed direct and indirect medical and surgical pentobarbital coma. METHODS: Retrospective chart review of all patients with refractory status epilepticus treated with pentobarbital over a 1 year period at a large tertiary care center...
October 2016: Therapeutic Advances in Drug Safety
Prasad S Nishtala, Mohammed Saji Salahudeen
BACKGROUND: The global burden of diabetes is increasing worldwide. The aim of the study was to investigate the trends in use of antidiabetic medicines among older New Zealanders between 2005 and 2013, and to perform a separate analysis by age, sex, ethnicity, district health board domicile and socioeconomic deprivation index. METHODS: The study population included individuals' aged 65 years and older living in New Zealand (NZ) captured in the pharmaceutical collections...
October 2016: Therapeutic Advances in Drug Safety
Louise C Cope, Aseel S Abuzour, Mary P Tully
Nonmedical prescribing has been allowed in the United Kingdom (UK) since 1992. Its development over the past 24 years has been marked by changes in legislation, enabling the progression towards independent prescribing for nurses, pharmacists and a range of allied health professionals. Although the UK has led the way regarding the introduction of nonmedical prescribing, it is now seen in a number of other Western-European and Anglophone countries although the models of application vary widely between countries...
August 2016: Therapeutic Advances in Drug Safety
Rebecca Ryan, Sophie Hill
Inappropriate medicine use and polypharmacy create significant challenges for consumers and the health systems they live in, worldwide. In this review, we describe the evidence underpinning interventions directed primarily at healthcare consumers, including information provision, pharmacist-delivered interventions and practical supports, such as reminders to improve outcomes related to medicines. We identify a relatively small number of strategies that seem effective or promising: self-monitoring and self-management programmes, simplified dosing regimens and pharmacist-delivered interventions such as medication review...
August 2016: Therapeutic Advances in Drug Safety
Maria Lurenda Westergaard, Signe Bruun Munksgaard, Lars Bendtsen, Rigmor Højland Jensen
Medication-overuse headache (MOH) is a debilitating condition in which frequent and prolonged use of medication for the acute treatment of pain results in the worsening of the headache. The purpose of this paper is to review the most recent literature on MOH and discuss future avenues for research. MOH accounts for a substantial share of the global burden of disease. Prevalence is often reported as 1-2% but can be as high as 7% overall, with higher proportions among women and in those with a low socioeconomic position...
August 2016: Therapeutic Advances in Drug Safety
Jacob K Akintunde, C Abigail Irechukwu
BACKGROUND: The antipsychotic, haloperidol, is extremely efficient in the treatment of schizophrenia but its application is constrained because of irreversible adverse drug reactions. Hence, in this study, we investigate the differential effects of black seed oil on cholinesterase [acetylcholinesterase (AChE) and butrylcholinesterase (BuChE), ectonucleotidase (5'-nucleotidase), lactate dehydrogenase (LDH) and monoamine oxidase (MAO)] activities and relevant markers of oxidative stress in the cerebrum of haloperidol-induced neuronal-damaged rats...
August 2016: Therapeutic Advances in Drug Safety
Ahsan Saleem, Tahir M Khan
No abstract text is available yet for this article.
June 2016: Therapeutic Advances in Drug Safety
Michael Joseph Scalese
No abstract text is available yet for this article.
June 2016: Therapeutic Advances in Drug Safety
Natalia Krzyzaniak, Beata Bajorek
OBJECTIVE: The objective of this study was to describe the medication errors in hospitalized patients, comparing those in neonates with medication errors across the age spectrum. METHOD: In tier 1, PubMed, Embase and Google Scholar were searched, using selected MeSH terms relating to hospitalized paediatric, adult and elderly populations. Tier 2 involved a search of the same electronic databases for literature relating to hospitalized neonatal patients. RESULTS: A total of 58 articles were reviewed...
June 2016: Therapeutic Advances in Drug Safety
Manfred Hauben, Eric Y Hung
INTRODUCTION: There is an interest in methodologies to expeditiously detect credible signals of drug-induced pancreatitis. An example is the reported signal of pancreatitis with rasburicase emerging from a study [the 'index publication' (IP)] combining quantitative signal detection findings from a spontaneous reporting system (SRS) and electronic health records (EHRs). The signal was reportedly supported by a clinical review with a case series manuscript in progress. The reported signal is noteworthy, being initially classified as a false-positive finding for the chosen reference standard, but reclassified as a 'clinically supported' signal...
June 2016: Therapeutic Advances in Drug Safety
Seth Strawbridge, Michael D Nailor
BACKGROUND: High doses of β-lactam antibiotics have been advocated for acute pulmonary exacerbations caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF) secondary to high minimum inhibitory concentrations (MIC) of the infecting organisms. Some β-lactam antibiotics have increased elimination in CF patients. This case series examines the safety of high-dose doripenem (HDD), 2 g intravenously every 8 hours, which is 4 times the labeled dose, in CF patients. METHODS: This was a retrospective, single site, chart review of all CF patients given HDD during a 3-year period...
June 2016: Therapeutic Advances in Drug Safety
Henna Hiltunen, Edwin C K Tan, Jenni Ilomäki, Sarah N Hilmer, Renuka Visvanathan, Tina Emery, Leonie Robson, Mary J Jones, Sirpa Hartikainen, J Simon Bell
OBJECTIVE: Depressive symptoms are highly prevalent in residential aged care facilities (RACFs). The prevalence of antidepressant use is increasing but the effectiveness of antidepressants in people with dementia is uncertain. The objective of the study was to investigate factors associated with antidepressant use in residents with and without dementia. METHODS: This was a prospective cross-sectional study of 383 residents in six Australian RACFs. Data on health status, medications and demographics were collected by trained study nurses from April to August 2014...
June 2016: Therapeutic Advances in Drug Safety
Michael J Scalese, Holly R Herring, R Chris Rathbun, Grant H Skrepnek, Toni L Ripley
OBJECTIVES: Propofol is a preferred agent for sedation in patients in the intensive care unit (ICU) due, in part, to its established safety profile. Despite this, recent case reports have suggested a potential for prolongation of the corrected QT interval (QTc) in ICU patients receiving propofol, though limited empirical work has been conducted to evaluate this association. As such, the purpose of this study was to assess the relationship between propofol infusion and QTc prolongation in a historical cohort of ICU patients...
June 2016: Therapeutic Advances in Drug Safety
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"